Recombinant platelet factor 4 for heparin neutralization.

abstract：:The purpose of this article is to review the use of blood products and hemostatic agents in the management of coagulopathy at the time of postpartum hemorrhage. Blood product administration strategies are broadly reviewed, including the role of the blood bank, the role of massive transfusion protocols, the role of lab...

journal_title：Seminars in thrombosis and hemostasis

authors： James AH,Grotegut C,Ahmadzia H,Peterson-Layne C,Lockhart E

更新日期：2016-10-01 00:00:00

abstract：:Central venous catheters (CVCs) are important for the treatment of patients with cancer, especially in the perioperative and palliative care settings. These devices not only allow for the administration of chemotherapy, parenteral nutrition, and other intravenous therapies, but they may also improve the patients' qual...

journal_title：Seminars in thrombosis and hemostasis

authors： Linnemann B

更新日期：2014-04-01 00:00:00

abstract：:As the understanding of the genetic basis of the inherited thrombophilias has increased over recent years, their routine diagnostic genetic analysis has also matured. This review considers methods used to test for the factor V (F5) Leiden mutation and prothrombin 20210A (F2 c.*97G>A) allele, and analysis of the SERPIN...

journal_title：Seminars in thrombosis and hemostasis

authors： Cooper PC,Goodeve AC,Beauchamp NJ

更新日期：2012-09-01 00:00:00

abstract：:Heparin is a familiar anticoagulant drug with properties that may impede tumor growth; it modifies properties of cells that contribute to malignant dissemination such as angiogenesis, growth factor and protease activity, immune function, proliferation, and gene expression. Heparin has antitumor effects in animal model...

journal_title：Seminars in thrombosis and hemostasis

authors： Zacharski LR,Ornstein DL,Mamourian AC

更新日期：2000-01-01 00:00:00

abstract：:Severe acute inflammation in chronic inflammatory bowel disease is associated with large wound areas and ulcerations that show spontaneous hemorrhage or marked friability. Therefore, an enormous potential of hemostasis and wound healing is required. Coagulation studies demonstrate a deficiency of factor XIII that is i...

journal_title：Seminars in thrombosis and hemostasis

authors： Lorenz R,Olbert P,Born P

更新日期：1996-01-01 00:00:00

abstract：:Thrombotic events are very frequent and represent the main cause of morbidity and mortality in patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), mainly polycythemia vera and essential thrombocythemia. Pathogenesis of blood clotting activation in these diseases is multifactorial, and i...

journal_title：Seminars in thrombosis and hemostasis

authors： Falanga A,Marchetti M

更新日期：2014-04-01 00:00:00

abstract：:For most cells the nucleus takes center stage. Not only is it the largest organelle in eukaryotic cells, it carries most of the genome and transcription of DNA to RNA largely takes place in the nucleus. Because transcription is a major step in gene regulation, the absence of a nucleus is limiting from a biosynthetic s...

journal_title：Seminars in thrombosis and hemostasis

authors： Weyrich AS,Lindemann S,Tolley ND,Kraiss LW,Dixon DA,Mahoney TM,Prescott SP,McIntyre TM,Zimmerman GA

更新日期：2004-08-01 00:00:00

abstract：:Total fibrinolytic activity in the vasculature is finely tuned by the balance between tissue plasminogen activator and plasminogen activator inhibitor type 1 (PAI-1). Although PAI-1 targets plasminogen activators, it also reacts with other serine proteases such as thrombin and factor Xa. The latter was shown to intera...

journal_title：Seminars in thrombosis and hemostasis

authors： Urano T,Ihara H,Suzuki Y,Takada Y,Takada A

更新日期：2000-01-01 00:00:00

abstract：:Pregnancy is associated with a significant procoagulant shift in the hemostatic system balance as well as other metabolic changes. Pregnancy can thereby provoke manifestation of otherwise dormant disorders of hemostasis (e.g., thrombophilia), or even cause new, pregnancy-specific disorders (e.g., HELLP syndrome). Appl...

journal_title：Seminars in thrombosis and hemostasis

authors： Ataullakhanov FI,Koltsova EM,Balandina AN,Serebriyskiy II,Vuimo TA,Panteleev MA

更新日期：2016-10-01 00:00:00

abstract：:Unfractionated heparin and LMMH were substituted with different lipophilic organic compounds. Specifically endpoint attached (LMMH-tyramine and LMMH-tyramine-FITC) and nonspecifically substituted heparins (acylated heparins, and LMMH-biotin and LMMH-cholesterol hemisuccinate) were obtained. The lipophilically substitu...

journal_title：Seminars in thrombosis and hemostasis

authors： Malsch R,Harenberg J,Guerrini M,Torri G,Casu B,Heene DL

更新日期：1994-01-01 00:00:00

abstract：:Self-control and self-management of oral anticoagulant therapy have become more and more attractive for patients undergoing long-term treatment. In our training center, we examined 50 patients who took part in a standardized training course for self-management. Patients (36 men, 14 women) were preselected according to...

journal_title：Seminars in thrombosis and hemostasis

authors： Mörsdorf S,Erdlenbruch W,Taborski U,Schenk JF,Erdlenbruch K,Novotny-Reichert G,Krischek B,Wenzel E

更新日期：1999-01-01 00:00:00

abstract：:Hemorrhagic complications during therapy with anticoagulant drugs have long been considered as simply and directly related to overdosage. Yet, such adverse events have also been observed in patients correctly anticoagulated, i.e., within the therapeutic range, thus demonstrating that the predictive value of laboratory...

journal_title：Seminars in thrombosis and hemostasis

authors： Toulemonde F

更新日期：1996-01-01 00:00:00

abstract：:The age of the thrombus is probably a very important determinant of the outcome of thrombolysis. The clinical potential for rapidly dissolving thrombi by thrombolytic therapy is considerable because restoration of the blood flow can rescue the jeopardized district served by the occluded vessel such as for myocardial i...

journal_title：Seminars in thrombosis and hemostasis

authors： Niada R,Porta R,Pescador R,Mantovani M,Prino G

更新日期：1989-10-01 00:00:00

abstract：:Most plasma proteins are present in both normal and atherosclerotic intima, and their concentrations in intimal interstitial fluid are directly related to plasma concentration and molecular size. All intimal samples also contain soluble fibrin-fibrinogen-related antigens, consisting of variable mixtures of fibrinogen ...

journal_title：Seminars in thrombosis and hemostasis

authors： Smith EB,Crosbie L,Carey S

更新日期：1996-01-01 00:00:00

abstract：:Endothelial phenotypic heterogeneity plays an important role in the susceptibility of the cardiovascular system to disease. Arteries and heart valves are susceptible to chronic inflammatory disease in regions of blood flow disturbance that implicates hemodynamic forces and transport characteristics as prominent influe...

journal_title：Seminars in thrombosis and hemostasis

authors： Davies PF,Civelek M,Fang Y,Guerraty MA,Passerini AG

更新日期：2010-04-01 00:00:00

abstract：:This article explores the application of viscoelastic tests (VETs) in trauma-induced coagulopathy and trauma resuscitation. We describe the advantages of VETs over conventional coagulation tests in the trauma setting and refer to previous disciplines in which VET use has reduced blood product utilization, guided prohe...

journal_title：Seminars in thrombosis and hemostasis

authors： Hartmann J,Walsh M,Grisoli A,Thomas AV,Shariff F,McCauley R,Vande Lune S,Zackariya N,Patel S,Farrell MS,Sixta S,March R,Evans E,Tracy R,Campello E,Scărlătescu E,Agostini V,Dias J,Greve S,Thomas S

更新日期：2020-03-01 00:00:00

abstract：:Low-molecular-weight heparins (LMWHs) are now universally accepted as drugs of choice for postsurgical prophylaxis and treatment of deep vein thrombosis (DVT). Currently, these agents are also being developed for the treatment of various cardiovascular conditions. Because of manufacturing differences, each of the LMWH...

journal_title：Seminars in thrombosis and hemostasis

authors： Fareed J,Ma Q,Florian M,Maddineni J,Iqbal O,Hoppensteadt DA,Bick RL

更新日期：2004-02-01 00:00:00

abstract：:The extrinsic pathway is probably the predominant pathway in initiating blood coagulation in inflammatory lung diseases. Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor of factor VIIa/tissue factor in the presence of factor Xa. As it has been shown recently that TFPI plasma levels are increa...

journal_title：Seminars in thrombosis and hemostasis

authors： Cella G,Cipriani A,Tommasini A,Rampin E,Sbarai A,Rocconi R,Mazzaro G,Luzzatto G

更新日期：1997-01-01 00:00:00

abstract：:Morbidity and mortality for cardiovascular disease are likely to be lower in patients with hemophilia than in the general male population. However, their clinical impact is increasing in parallel with the increase of life expectancy due to modern safe replacement treatments and the improvement of comprehensive care of...

journal_title：Seminars in thrombosis and hemostasis

authors： Coppola A,Tagliaferri A,Franchini M

更新日期：2010-02-01 00:00:00

abstract：:Natural inhibitors of coagulation, in other words, antithrombin (AT), the protein C system, and tissue factor pathway inhibitor (TFPI), play an important role in controlling the activation of coagulation during disseminated intravascular coagulation (DIC). Furthermore, they may not only influence coagulation but also ...

journal_title：Seminars in thrombosis and hemostasis

authors： de Jonge E,van der Poll T,Kesecioglu J,Levi M

更新日期：2001-12-01 00:00:00

abstract：:Rapid and accurate risk stratification is critical in determining the optimal treatment strategy for patients with acute pulmonary embolism (PE). Early identification of patients with normal blood pressure and a favorable prognosis (low-risk PE) might select a subset of patients for outpatient treatment, which is asso...

journal_title：Seminars in thrombosis and hemostasis

authors： Morillo R,Moores L,Jiménez D

更新日期：2017-07-01 00:00:00

abstract：:Congenital factor XIII (FXIII) deficiency is a rare, autosomal recessive bleeding disorder with potentially life-threatening consequences. FXIII is composed of two subunits (A and B), and a deficiency or dysfunction of either can result in FXIII deficiency. Traditionally, FXIII deficiency has been managed by infusing ...

journal_title：Seminars in thrombosis and hemostasis

authors： Carcao M,Fukutake K,Inbal A,Kerlin B,Lassila R,Oldenburg J,Garly ML,Nugent D

更新日期：2017-02-01 00:00:00

abstract：:Plasma-derived factor concentrates are important in the management of von Willebrand disease (VWD). We review the current literature regarding pharmacokinetic studies of von Willebrand factor (VWF) concentrates used to treat VWD. Using additional local experience of a crossover pharmacokinetic (PK) study comparing a c...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ,Kershaw G,McLachlan AJ,Lloyd J

更新日期：2007-11-01 00:00:00

abstract：:The quiescent vascular system in the adult body represents the imbalanced net outcome of overproduction of endogenous angiogenesis inhibitors and reduced levels of angiogenic factors. While some endogenous inhibitors are expressed under physiological conditions, they can also be generated in association with tumor gro...

journal_title：Seminars in thrombosis and hemostasis

authors： Cao Y,Xue L

更新日期：2004-02-01 00:00:00

abstract：:Approximately 5 to 7% of patients with hemophilia A have inhibitory antibodies to factor (F) VIII, which increases to approximately 13% in patients with severe disease. The strongest determinant of the risk of inhibitor development identified is the type of mutation in the FVIII gene that gives rise to the disease. Ho...

journal_title：Seminars in thrombosis and hemostasis

authors： Lee CA,Lillicrap D,Astermark J

更新日期：2006-06-01 00:00:00

abstract：:In addition to the criteria of the Polycythemia Vera Study Group, positive markers for essential thrombocythemia (ET) include spontaneous BFU-E, splenomegaly, and megakaryocyte morphology in bone marrow smears and biopsy material. The hematologic features of 11 reported cases of ET in childhood showed platelet counts ...

journal_title：Seminars in thrombosis and hemostasis

authors： Michiels JJ,Van Genderen PJ

更新日期：1997-01-01 00:00:00

abstract：:Numerous studies, performed in recent years, have provided the convincing demonstration that the incidence of newly diagnosed malignancy is increased among patients with unexplained venous thromboembolism during the first 6 to 12 months after the thromboembolic event. Among malignancies presenting with venous thromboe...

journal_title：Seminars in thrombosis and hemostasis

authors： Monreal M,Prandoni P

更新日期：1999-01-01 00:00:00

abstract：:von Willebrand disease (vWD) is the commonest bleeding disorder in women. More than 70% of women with vWD suffer from menorrhagia and half of them suffer from dysmenorrhea. There is also the risk of hemorrhage with ovulation and mid-cycle pain. These have a significant effect on all aspects of quality of life. vWD als...

journal_title：Seminars in thrombosis and hemostasis

authors： Kadir RA,Chi C

更新日期：2006-09-01 00:00:00

abstract：:Life expectancy for persons with hemophilia (PWH) has considerably increased in the last decades as a direct result of the availability of modern therapies to control the clotting defect. Because their life expectancy now matches that of the general population, PWH are experiencing age-related comorbidities, such as, ...

journal_title：Seminars in thrombosis and hemostasis

authors： Coppola A,Santoro C,Franchini M,Mannucci C,Mogavero S,Molinari AC,Schinco P,Tagliaferri A,Santoro RC

更新日期：2013-10-01 00:00:00

abstract：:Platelet-lowering therapy in myeloproliferative disorders includes cytostatic drugs, mainly hydroxyurea, interferon alpha, and anagrelide. Anagrelide is the latest addition to the therapeutic arsenal, and the basis for its use is reviewed. The platelet-lowering efficacy is 70 to 80% in essential thrombocythemia, and t...

journal_title：Seminars in thrombosis and hemostasis

authors： Birgegard G

更新日期：2006-04-01 00:00:00